Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million

Reuters

Yesterday

Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million

Mabion SA reported third quarter (Q3) 2025 revenue of PLN 4.1 million, representing a multiple of nearly 7 times year-on-year growth. For the first nine months (9M) of 2025, revenue amounted to PLN 10.1 million, down 84.4 percent year-on-year. The net result for Q3 2025 was a loss of PLN 10.8 million, an improvement of 34 percent compared to the same period last year. EBITDA for Q3 2025 stood at minus PLN 8.4 million, also an improvement of 34.7 percent year-on-year. Cash at the end of Q3 2025 totaled PLN 4.6 million, declining by PLN 6.2 million quarter-on-quarter. The company secured additional bridge financing of PLN 18 million after the balance sheet date. Mabion SA's revenue in Q3 2025 was primarily driven by services provided to Novavax and other CDMO projects. The company maintained high cost discipline and reported marginal capital expenditures of PLN 0.2 million in the quarter. Mabion SA continues to focus on technology, operational excellence, and portfolio diversification, with expectations to reach break-even and transition to profitability by the end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabion SA published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2588035267"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588035267\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588035267?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588035267","market":"nz","top_or_hot":-1,"title":"Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mabion SA reported third quarter (Q3) 2025 revenue of PLN 4.1 million, representing a multiple of nearly 7 times year-on-year growth. For the first nine months (9M) of 2025, revenue amounted to PLN 10.1 million, down 84.4 percent year-on-year. The net result for Q3 2025 was a loss of PLN 10.8 million, an improvement of 34 percent compared to the same period last year. EBITDA for Q3 2025 stood at minus PLN 8.4 million, also an improvement of 34.7 percent year-on-year. Cash at the end of Q3 2025 totaled PLN 4.6 million, declining by PLN 6.2 million quarter-on-quarter. The company secured additional bridge financing of PLN 18 million after the balance sheet date. Mabion SA's revenue in Q3 2025 was primarily driven by services provided to Novavax and other CDMO projects. The company maintained high cost discipline and reported marginal capital expenditures of PLN 0.2 million in the quarter. Mabion SA continues to focus on technology, operational excellence, and portfolio diversification, with expectations to reach break-even and transition to profitability by the end of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabion SA published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabion SA Q3 revenue surges sevenfold to PLN 4.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mabion SA reported third quarter (Q3) 2025 revenue of PLN 4.1 million, representing a multiple of nearly 7 times year-on-year growth. For the first nine months (9M) of 2025, revenue amounted to PLN 10.1 million, down 84.4 percent year-on-year. The net result for Q3 2025 was a loss of PLN 10.8 million, an improvement of 34 percent compared to the same period last year. EBITDA for Q3 2025 stood at minus PLN 8.4 million, also an improvement of 34.7 percent year-on-year. Cash at the end of Q3 2025 totaled PLN 4.6 million, declining by PLN 6.2 million quarter-on-quarter. The company secured additional bridge financing of PLN 18 million after the balance sheet date. Mabion SA's revenue in Q3 2025 was primarily driven by services provided to Novavax and other CDMO projects. The company maintained high cost discipline and reported marginal capital expenditures of PLN 0.2 million in the quarter. Mabion SA continues to focus on technology, operational excellence, and portfolio diversification, with expectations to reach break-even and transition to profitability by the end of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabion SA published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL82C4jm:1","article_id":"2588035267","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588035267","pubTimestamp":1764666296,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mabion SA reported third quarter  2025 revenue of PLN 4.1 million, representing a multiple of nearly 7 times year-on-year growth. For the first nine months  of 2025, revenue amounted to PLN 10.1 million, down 84.4 percent year-on-year. The net result for Q3 2025 was a loss of PLN 10.8 million, an improvement of 34 percent compared to the same period last year. EBITDA for Q3 2025 stood at minus PLN 8.4 million, also an improvement of 34.7 percent year-on-year. Cash at the end of Q3 2025 totaled PLN 4.6 million, declining by PLN 6.2 million quarter-on-quarter. The company secured additional bridge financing of PLN 18 million after the balance sheet date. Mabion SA's revenue in Q3 2025 was primarily driven by services provided to Novavax and other CDMO projects. The company maintained high cost discipline and reported marginal capital expenditures of PLN 0.2 million in the quarter. Mabion SA continues to focus on technology, operational excellence, and portfolio diversification, with expe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BK4568":"美国抗疫概念","BK4588":"碎股","BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Mabion SA第三季度收入猛增七倍至410万兹罗提","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million\n    \n\n        Mabion SA reported third quarter (Q3) 2025 revenue of PLN 4.1 million, representing a multiple of nearly 7 times year-on-year growth. For the first nine months (9M) of 2025, revenue amounted to PLN 10.1 million, down 84.4 percent year-on-year. The net result for Q3 2025 was a loss of PLN 10.8 million, an improvement of 34 percent compared to the same period last year. EBITDA for Q3 2025 stood at minus PLN 8.4 million, also an improvement of 34.7 percent year-on-year. Cash at the end of Q3 2025 totaled PLN 4.6 million, declining by PLN 6.2 million quarter-on-quarter. The company secured additional bridge financing of PLN 18 million after the balance sheet date. Mabion SA's revenue in Q3 2025 was primarily driven by services provided to Novavax and other CDMO projects. The company maintained high cost discipline and reported marginal capital expenditures of PLN 0.2 million in the quarter. Mabion SA continues to focus on technology, operational excellence, and portfolio diversification, with expectations to reach break-even and transition to profitability by the end of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabion SA published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}